First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2017-05-03
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group,
dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor
activity of FLX925 in subjects with relapsed or refractory AML.